The important role of commensal flora as a natural reservoir of bacterial resistance is now well established. However, whether the behavior of each commensal flora is similar to that of other floras in terms of rates of carriage and risk factors for bacterial resistance is unknown. During a 6-month period, we prospectively investigated colonization with fluoroquinolone-resistant bacteria in the three main commensal floras from hospitalized patients at admission, targeting Escherichia coli in the fecal flora, coagulase-negative Staphylococcus (CNS) in the nasal flora, and ␣-hemolytic streptococci in the pharyngeal flora. Resistant strains were detected on quinolone-containing selective agar. Clinical and epidemiological data were collected. A total of 555 patients were included. Carriage rates of resistance were 8.0% in E. coli, 30.3% in CNS for ciprofloxacin, and 27.2% in streptococci for levofloxacin; 56% of the patients carried resistance in at least one flora but only 0.9% simultaneously in all floras, which is no more than random. Risk factors associated with the carriage of fluoroquinolone-resistant strains differed between fecal E. coli (i.e., colonization by multidrug-resistant bacteria) and nasal CNS (i.e., age, coming from a health care facility, and previous antibiotic treatment with a fluoroquinolone) while no risk factors were identified for pharyngeal streptococci. Despite high rates of colonization with fluoroquinolone-resistant bacteria, each commensal flora behaved independently since simultaneous carriage of resistance in the three distinct floras was uncommon, and risk factors differed. Consequences of environmental selective pressures vary in each commensal flora according to its local specificities (clinical trial NCT00520715 [http://clinicaltrials.gov/ct2/show/NCT00520715]).
Bacterial resistance to antibiotics is a growing problem that results in prolonged hospital stays and increased antibiotic use, morbidity, mortality, and cost (28) . Resistance to antibiotics, including fluoroquinolones, is the result of direct selection at the site of infection or in the commensal flora. The role of the commensal flora as a natural reservoir of bacterial resistance may even be more important than the infectious foci as higher numbers of bacteria and species are present, allowing multiple horizontal gene transfers to pathogens as well as direct infection by commensal bacteria (1, 2, 37) . Additionally, microbiota may repeatedly be affected by any antibiotic treatment, whether or not the drugs are used to treat a bacterial infection, whereas resistant pathogens can emerge from the infectious foci only in patients actually infected (32, 38, 40) .
Fluoroquinolones are highly active antibiotics with a lowtoxicity profile, large spectrum, and excellent tissular diffusion. These advantages explain their wide use for both community and nosocomial infections (23) and their drawback: the rapid and preoccupying emergence of resistance to fluoroquinolones worldwide (8, 24, 32) . Decreased susceptibility to fluoroquinolones arises mainly as a result of single-step mutations in the quinolone target genes encoding the topoisomerase enzymes (18) , conferring cross-resistance to all fluoroquinolones (8) . More recently, plasmid-borne mechanisms of resistance have been described, suggesting that horizontal transfer may play a more important role than predicted (26, 35) . Accumulation of multiple mutations in several genes confers increasing levels of resistance with clinical failures (20) , but even low-level resistance can generate therapeutic failure (11) . Understanding the factors involved in the emergence of fluoroquinolone-resistant bacteria in commensal flora would help prevent their spread and identify individual patients at risk of infections by resistant bacteria. To achieve this, all floras need to be addressed at once. Indeed, although the different floras are in theory exposed to the same environmental conditions and selective pressures from previous antibiotic treatments, risk factors for carrying fluoroquinolone-resistant strains in a given patient may differ, in particular because microorganisms differ, and concentrations of antibiotics vary according to each commensal specificity. Previous works, however, focused only on a specific commensal flora at once (6, 15, 27, 34) . The three main floras in humans are the oropharyngeal, the fecal, and the nasal floras. Multiple bacterial species share these floras, but ␣-hemolytic streptococci in the oropharyngeal flora, Escherichia coli in the fecal flora, and coagulase-negative staphylococci (CNS) in the nasal flora are of particular importance as they are present in all subjects, are frequently involved in invasive and opportunistic infections, and are recognized sources of horizontal transfer within the commensal flora (5, 43) . We chose to investigate a population of patients at their admission to hospital as they are at high risk of colonization by resistant bacteria, are a known source of dissemination, and are at risk of treatment failures resulting from use of the wrong antibiotics.
The aim of this work is to describe the prevalence and determine the risk factors associated with the carriage of fluoroquinolone-resistant strains of these target species in the commensal flora of patients admitted to hospital and to assess whether these risk factors are common to the different floras.
MATERIALS AND METHODS
Study population and sample collection. We conducted a prospective cohort study including patients admitted to four medical wards (internal medicine department, 36 beds; cardiology, geriatric, and oncology departments, 10 beds each) of our 500-bed tertiary-care teaching hospital from 1 June to 30 October 2007. All adult patients admitted for more than 24 h during the study period in one of these wards were included only once. For all patients, nasal, oropharyngeal, and rectal swabs were performed, and clinical data were collected within 48 h of admission at the hospital by the same investigator. This work was approved by the French National Ethics Committee.
Data collection. For each patient, data collection included demographic information, the Charlson comorbidity index score (12) , data on previous hospital stays, place of residency before hospitalization (home or transfer from another hospital, nursing home, or a long-term care facility), previous exposure to antibiotics (antibiotic class, duration of treatment, and delay since the end of treatment) over the last 3 months, current antibiotic treatments, and history of carriage or infection by a multidrug-resistant (MDR) bacteria in the last year. Concerning the consumption of antibiotics in the last 3 months, medical charts were reviewed, patients were asked about personal antibiotic consumption, and prescriptions and drug dispensations were double-checked.
Microbiological methods. For each patient, the three swabs were separately discharged in 1 ml of brain heart infusion (BHI) broth, stored at Ϫ80°C, and blinded with respect to patient identification. Broths were then processed separately, with 100 l spread onto agar plates with and without selective antibiotics. Each nasal sample was plated on two Chapman agar plates (bioMérieux, Marcy l'Etoile, France) with and without 2 g/ml ciprofloxacin. Rectal samples were plated on three Drigalski agar plates (Pasteur Diagnostics, Paris, France), one containing no antibiotics, one with 16 g/ml nalidixic acid, and one with 1 g/ml ciprofloxacin. Oropharyngeal samples were plated on two Columbia colistin-nalidixic acid (CNA) agar plates (15 g/ml nalidixic acid, 10 g/ml colistin, and 5% blood; bioMérieux, Marcy l'Etoile, France) with and without 4 g/ml levofloxacin. Resistance to levofloxacin was used to detect emergence of resistance in pharyngeal streptococci because they are naturally resistant to ciprofloxacin and, therefore, there are no ciprofloxacin MIC breakpoints. Levofloxacin is additionally widely recommended for the treatment of respiratory infections (25) . Additionally, emergence of resistance to levofloxacin in pharyngeal ␣-hemolytic streptococci obviates the selection of cross-resistance among fluoroquinolones, as shown for Streptococcus pneumoniae (8) .
Plates were incubated at 37°C for 48 h in an aerobic atmosphere, enriched in CO 2 for the oropharyngeal samples. If cultures were positive on the fluoroquinolone-containing plates, three colonies were picked randomly and stored together at Ϫ80°C.
Mannitol-negative and mannitol-positive colonies from Chapman agar, lactose-positive ones from Drigalski agar, and ␣-hemolytic ones from CNA agar were identified as coagulase-negative staphylococci and Staphylococcus aureus, E. coli, and ␣-hemolytic streptococci, respectively, using conventional techniques. All patients were screened for the carriage of extended-spectrum ␤-lactamase (ESBL)-producing enterobacteria in the fecal flora by plating samples on Drigalski agar plates with 1 g/ml cefotaxime. Enterobacteria growing on the cefotaxime-supplemented Drigalski agar were identified to the species level, and their susceptibilities to antibiotics were determined using the disk diffusion method, as recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST [http://www.eucast .org]). ESBL production was detected using a clavulanic synergy test as described previously (19) . Carriage of methicillin-resistant S. aureus (MRSA) in the nasal flora was systematically screened by determining susceptibilities to cefoxitin, oxacillin, and aminoglycosides. MICs of fluoroquinolones were determined for each of the target species by the agar dilution method (39), using breakpoints established by the EUCAST. Resistance was defined by the detection of coagulase-negative staphylococci or S. aureus in the nasal flora at a ciprofloxacin MIC of Ͼ1 g/ml, the detection of E. coli in the fecal flora at a ciprofloxacin MIC of Ͼ1 g/ml, and the detection of ␣-hemolytic streptococci in the oropharyngeal flora at a levofloxacin MIC of Ͼ2 g/ml. First, levels of quinolone resistance in E. coli were screened using resistance to nalidixic-acid (MIC of Ͼ16 g/ml) as a surrogate marker. Statistical analysis. Risk factors for carriage of nalidixic acid-resistant E. coli, of ciprofloxacin-resistant E. coli, CNS, and S. aureus, and of levofloxacinresistant ␣-hemolytic streptococci were analyzed by univariate and then multivariate analysis by using a logistic regression model. All variables that were associated with fluoroquinolone resistance at a P value of Ͻ0.2 (Wald test) in univariate analysis were included in a multivariate analysis in a stepwise manner to construct the final model, with a P value of Ͻ0.05 considered significant.
RESULTS

Patients.
During the 5-month study period, 620 adult patients were admitted to one of the medical wards of our hospital. Of the patients, 24 refused to participate, and 41 had already been included during a previous hospitalization. Altogether 555 patients were finally included. Among them, 44 (7.9%) refused the rectal swabs but accepted the other swabs; therefore, 511 had all three swabs performed. Characteristics of patients are reported in Table 1 .
Prevalence of resistance. Prevalence of resistance for each flora is summarized in Table 2 . Concerning the rectal swabs, although the broth in which they were discharged always grew bacteria when plated on Mueller-Hinton medium, antibiotic-free Drigalski plates failed to grow E. coli in 151/511 cases (29%). Thus, only 360 patients (64.8%) carried E. coli in their fecal flora. Altogether, 42 patients (8.0% of total population and 11.4% of the E. coli positive cultures) carried ciprofloxacin-resistant E. coli in their fecal flora. An additional 35 patients (6.8%) carried E. coli strains resistant to nalidixic acid but susceptible to ciprofloxacin.
For nasal and oropharyngeal floras, antibiotic-free agar plates growing no CNS/S. aureus or ␣-hemolytic streptococci were uncommon (6 and 3%, respectively). Concerning the nasal flora, 168 patients (30.3%) carried ciprofloxacin-resistant coagulase-negative staphylococci, 96 (17.2%) carried S. aureus, and among them 22 carried ciprofloxacin-resistant strains (4.0% of the whole population, or 23% of S. aureus carriers).
For the oropharyngeal flora, 151 (27.2%) patients carried levofloxacin-resistant ␣-hemolytic streptococci.
Altogether, 310 patients (56%) carried fluoroquinoloneresistant strains in at least one of the three floras tested, but only 5 patients (0.9%) carried resistance simultaneously in the three floras, which is no more than the product of resistance rates found for each flora (8% ϫ 30.3% ϫ 27.2% ϭ 0.7%) ( Table 3) .
Risk factors associated with resistance. Results of the univariate and multivariate analysis for ciprofloxacin-resistant E. coli, ciprofloxacin-resistant staphylococci, and levofloxacin-resistant streptococci are reported in Tables 4 to 7 . Compared to patients carrying ciprofloxacin-sensitive strains, carriage of ciprofloxacinresistant E. coli in the fecal flora was significantly associated with older age, not coming from home, prior antibiotic treatment, in particular, with a ␤-lactam or a fluoroquinolone, having received more than a week's course of antibiotics in the last 3 months, and colonization by a multidrug resistant (MDR) bacteria (MRSA or ESBL) and by an ESBL-producing bacteria in particular. Compared to patients carrying nalidixic acid-sensitive strains, carriage of nalidixic acid-resistant E. coli in the fecal flora was not significantly associated with any of the risk factors screened. In the multivariate analysis, the only variable significantly associated with colonization with ciprofloxacin-resistant E. coli was the carriage of multidrug-resistant bacteria (either MRSA in the nasal flora or ESBL-producing Enterobacteriaceae in the fecal flora).
For ␣-hemolytic streptococci, patients having received antibiotics, in particular ␤-lactams, in the previous 3 months and having had more than 7 days of treatment seemed to be protected from the carriage of levofloxacin-resistant strains in the oropharyngeal flora, according to the univariate analysis. In the multivariate analysis, patients treated between 1 For ciprofloxacin-resistant coagulase-negative staphylococci, many variables were associated with the carriage of resistance in the univariate analysis, in particular, older age, coming from a health care facility, a previous hospital stay in the last year, and having received antibiotics in the last 3 months, including fluoroquinolones and ␤-lactams. In the multivariate analysis, older age, coming from a health care facility before hospitalization, and having received more than 7 days of any antibiotic in the last 3 months were factors significantly associated with the carriage of ciprofloxacin-resistant strains.
Risk factors for the carriage of ciprofloxacin-resistant S. aureus were a higher comorbidity score, the consumption of fluoroquinolones in the last 3 months, and the past or present carriage of MRSA. Among the 96 patients carrying S. aureus, 14 (14.9%) were MRSA carriers, and all MRSA strains were ciprofloxacin resistant. In the multivariate analysis, older age and having received a fluoroquinolone in the last 3 months were significantly associated with ciprofloxacin resistance.
DISCUSSION
This work is, to our knowledge, the first to analyze the behavior of distinct commensal floras from hospitalized patients regarding the carriage of fluoroquinolone resistance.
Despite the high prevalence of fluoroquinolone resistance observed in this cohort of patients, each flora appeared to behave differently. Indeed, from a quantitative point of view, the observed prevalence of simultaneous carriage of resistance in the three floras at once (0.9%) was similar to the calculated risk according to the prevalence of resistance in each flora. Additionally, the nature of the risk factors differed from one flora to another although some commonalities exist. Therefore, carrying fluoroquinolone-resistant strains in all three commensal floras at once appears to be random, despite the fact that each patient was exposed to the same environmental conditions. This phenomenon may be explained by several factors.
First, nearly half the patients had been treated by antibiotics in the last 3 months, and most of them had probably received antibiotics in their lifetimes. Additionally, antibiotics are widespread in the environment, making selective pressure difficult to avoid for patients and their flora. And yet variations in drug concentrations are a source of differential selective pressures on the commensal ecosystems. Indeed, antibiotic concentrations measured in the nasal secretions, saliva, and feces differ from those found in the infectious foci or the plasma but also differ, sometimes in very large proportions, from one flora to another, as shown for fluoroquinolones (10, 13, 17, 31 ). As we have previously shown, emergence of quinolone-resistant bacteria follows a different kinetic pattern over time in the pharyngeal and fecal floras of healthy volunteers, and the dynamics of clear- ance of resistance after antibiotic pressure are also different from one flora to another (13). Second, another major route for acquiring resistant bacteria is horizontal transfer (16) . The role of health care settings and hand-borne transmission has been widely documented for the transmission of resistant staphylococci and enterobacteria (16) , but the role of interindividual transfer of oral streptococci seems to be of less importance, although its role remains widely unknown (15) . Third, acquisition of bacterial resistance through direct ingestion of resistant bacteria from food (meat from farm animals exposed to antibiotics and also fruit and vegetables) cannot be undervalued and will affect predominantly the fecal flora (4, 36, 37) . The resistant bacteria enter the intestinal tracts and commingle with members of the resident human flora, potentially sharing resistant genes (22, 37) . In addition, humans may also absorb pathogenic members of the intestinal microflora itself (37) . Finally, the microenvironment of each flora is rich and distinct. Genetic exchanges take place between species, and the variety of these microenvironments and exchanges may explain differences between floras (1). Indeed, human commensal bacteria do not only share resistance genes among themselves but can also acquire from or donate resistance to bacteria that are just passing through (37) . These phenomena depend on the local environment, the species, and potential selective pressures involved in a mostly dynamic environment. In the oral flora, genes encoding fluoroquinolone resistance in oral streptococci can be transformed and expressed in S. pneumoniae, with the rate being higher when donor species are phylogenetically close to S. pneumoniae (15) . More recently, fluoroquinolone exposure has been shown to induce genetic transformability of S. pneumoniae (33) .
One important limitation to this work is the failure to find evidence of Enterobacteriaceae in as many as 27% of all rectal swabs. Rectal swabs have been shown to be very sensitive in detecting enteric bacteria compared to standard stool cultures (20) . No significant difference was found between the group in which E. coli was retrieved from the rectal swab and that in which it was not although patients without E. coli in their swabs tended to have received more antibiotics in the last 3 months (P ϭ 0.2) (data not shown), which may be an explanation for this phenomenon.
Previous fluoroquinolone exposure, as prophylaxis or treatment, has been found by others to be a significant risk factor for the isolation of fluoroquinolone-resistant Enterobacteriaceae from infectious foci (7, 14) . However, patients infected with susceptible organisms are unlikely to have previously received an agent that would be active against these organisms; therefore, comparing cases of fluoroquinolone-resistant with fluoroquinolone-susceptible infections is likely to overestimate the association of prior antimicrobial use (6) . Studying the commensal flora instead of infections provides less bias because all patients, infected or not, are screened. Works aimed to study the commensal flora have also found that previous fluoroquinolone exposure was a risk factor for the carriage of fluoroquinolone-resistant Enterobacteriaceae (3, 27, 34) . Here, previous fluoroquinolone exposure is more frequent in patients carrying fluoroquinolone-resistant strains in the univariate analysis, although not significantly, probably because of a lack of statistical power due to the smaller sample size (in univar- iate analyses, the odds ratio is 2.18 in this study and 7.71 and 2.1 for samples of 50 and 200 patients, respectively, in previous works) (27, 34) . Additionally, rates of resistance have risen constantly in the last 10 years, which may explain some changes in the epidemiology of resistance (21, 24) . In particular, nalidixic acid resistance in E. coli may now be so diffuse that no specific risk factor is associated with its carriage. Our results show that carriage of ciprofloxacin-resistant E. coli is associated with colonization by MDR bacteria. Therefore, selective antibiotic pressure on individual patients in high-prevalence areas of fluoroquinolone resistance among Enterobacteriaceae, as in the Paris area (21) , may now play a less important role than the interpatient spread of resistant strains, mimicking the dissemination of MRSA or ESBL-producing bacteria. Coselection between fluoroquinolone resistance and MDR bacteria has been well established as fluoroquinolone use has been associated with the selection of MRSA and other MDR bacteria (29, 30, 41, 42) . Concerning oral streptococci, it appears surprising that a short course of antibiotics would protect patients from colonization by fluoroquinolone-resistant strains of oral streptococci. Nearly a third of patients (28%) were treated by antibiotics at the time of sample collection, and most of them (58%) were receiving amoxicillin-clavulanic acid. Concentrations of oral streptococci diminish by at least 1 log under amoxicillin-clavulanic acid treatment (9); therefore, so do fluoroquinolone-resistant strains, which could explain difficulties in detecting fluoroquinolone-resistant streptococci. Others investigators found in a group of 60 patients that prior fluoroquinolone consumption had no impact on fluoroquinolone resistance in oral streptococci. They have also shown that there was no clonal diffusion of resistant streptococci in hospitalized patients, corroborating our findings (15) .
Finally, resistance to fluoroquinolones in S. aureus and in coagulase-negative staphylococci appears to be linked to antibiotic exposure and patient age, emphasizing the role of nasal staphylococci as reservoirs of resistance over time.
In conclusion, each flora in the same patient is submitted, in theory, to the same environmental conditions. Nevertheless, this work shows that despite some similarities in risk factors, each flora behaves differently toward fluoroquinolone resistance, to the point that carrying resistance in the three floras at once is no more than random, and carrying resistance in two of three floras is infrequent. Therefore, no simple intervention strategy may diminish the carriage of fluoroquinolone-resistant bacteria in all three commensal floras at once. Moreover, data from one flora cannot be extrapolated to others. Limiting antibiotic consumption as well as patient-to-patient transmission of resistant bacteria should be encouraged until we know more about the behavior of these complex ecosystems at a time when few new antibiotics are being developed. 
